About Us: Board of Directors
EMPOWERING A BOLD VISION
Our board members empower our culture, diversity and advancement as global leaders in a regenerative medicine company. Collectively, our advisors provide innovative solutions and industry-leading guidance to focus on patient care and medical successes made possible from their direction and insistence that only results change the way exceptional care is administered.
Mr. Panaccio was appointed as AVITA Medical Chairman of the Board in July 2014 with more than 30 years of executive leadership skills in healthcare and life sciences experience, including developing company concepts through finished commercialization.
Mr. Panaccio is positioned on additional Boards including Non-Executive Director of ASX50 company, one of the world’s largest medical diagnostics companies; Sonic Healthcare Limited since 2005; Non-Executive Director Unison Housing Limited; Non-Executive Chairman of Genera Biosystems Limited; and Non-Executive Director Rhythm Biosciences Limited. Mr. Panaccio’s past executive and board roles includ Melbourne Pathology Group, Monash IVF Group, Health Networks Australia Group and Primelife Corporation Limited.
Jeremy Curnock Cook
Mr. Curnock Cook was appointed to the AVITA Medical Board in October 2012. As the former leader of Rothschild Asset Management, a life science private equity firm, Mr. Curnock Cook was responsible for the launch of the first dedicated biotechnology fund for the Australian market, and the conception and launch of the International Biotechnology Trust.
As current Managing Director of Bioscience Managers Pty Ltd, Mr. Curnock Cook is responsible for the BSM Asia Pacific Healthcare Fund and is appointed to the Boards of AmpliPhi Bioscience Corporation Inc. (since 1995); Rex Bionics Pty Ltd (since 2017); International Bioscience Managers Ltd (since 2000); Adherium Ltd (since 2015); SummatiX Ltd (since 2017) and Arecor Ltd (since 2018). Previous appointments included Eacom Timber Corporation, Sirna Therapeutics Inc, and Biocompatibles International PLC.
Dr. Michael Perry
Chief Executive Officer & Executive Director
Dr. Mike Perry was appointed as Chief Executive Officer (CEO) of AVITA Medical in June 2017, after serving on the Board since February 2013. He brings extensive experience across the global pharmaceutical value chain for healthcare products spanning diverse therapeutic areas, including substantial expertise in cell therapies and cell-based gene therapies. In his career, he has been materially involved in the successful development and commercial launch of over 30 prescription products, 14 of which achieved blockbuster status.
Prior to joining AVITA, Dr. Perry’s leadership positions included Chief Scientific Officer of Novartis’ Cell and Gene Therapy Unit from 2014-2017; Vice President and Global Head of Stem Cell Therapy for Novartis Pharmaceuticals Corp. from 2012-2014.
With additional positions held as Global Head of R&D at Baxter Healthcare; President and CEO of Cell & Gene Therapy at Novartis affiliates Systemix Inc. and Genetic Therapy, Inc.; Vice President of Regulatory Affairs at Sandoz Pharmaceuticals Corporation; Director of Regulatory Affairs at Schering-Plough Corporation; and Venture Partner with Bay City Capital, LLC, Dr. Perry brings successful global management, guidance and forward direction to AVITA. Since 2011, has served as a Director with Arrowhead Pharmaceutical expanding his reach in influential medical growth.
Mr. Drapeau was appointed to the AVITA Medical Board in January 2016.
Mr. Drapeau’s current positions include Independent Director at AmphliPhi Biosciences Corporation (NYSE) and Independent Director at Surface Pharmaceuticals Inc; His previous senior positions included roles with InSite Vision Inc as CFO and Vice President; Independent Director at Bio-Rad Laboratories, Inc. (NYSE). Nektar Therapeutics as Senior Vice President and CFO, BioMarin Pharmaceutical, Inc. as Senior Vice President and CFO; Audit Partner at Arthur Andersen, LLP; Independent Director at InterMune, Inc. (NASDAQ); Bionovo, Inc. (NASDAQ); and Inflazyme Pharmaceuticals LTD (TSE).
Mr. Drapeau has a bachelor of science in Mechanical Engineering and an MBA, both from Stanford University.
Mr. McDonald was appointed to the AVITA Medical Board in January 2016. He holds an MBA from the Institute for Management Development (IMD) in Lausanne, Switzerland, a Master of Science in International Economics from the University of Wales, U.K.; a Bachelor of Economics degree and a Bachelor of Pharmacy degree, both from the University of Queensland, Australia.
Mr. McDonald is currently the Chief Executive Officer of LivaNova, a NASDAQ listed Medtech innovator. His previous roles included COO of LivaNova; Group Executive and Corporate Vice President at Danaher Corporation, leading a $1.5 billion group of dental consumables company; Group President at Kerr; Spine Division Leader at Zimmer; and J&J’s Medical Device Franchises, marketing the $2.5 billion medical device unit.
Professor Suzanne Crowe
Appointed to the AVITA Medical Board in January 2016, Prof. Crowe holds medical and MD degrees from Monash University, an internal medicine specialist qualification in Infectious Diseases from the Royal Australasian College of Physicians, and a Diploma in Medical Laboratory Technology from the Royal Melbourne Institute of Technology.
Prof. Crowe’s current positions include, Principal Specialist in Infectious Diseases at The Alfred Hospital, Melbourne; Adjunct Professor of Medicine and Infectious Diseases at Monash University, Melbourne; Member of the Australian Institute of Company Directors; Non-Executive Director of St Vincent’s Health Australia; and Appointed Member of the Order of Australia (AM) in 2011, recognizing her medical research service in HIV/AIDS.